| abstract |
The present invention relates to novel quinoline compounds of the formula I and to the salts thereof. The compounds possess valuable therapeutic properties and are particularly suitable, for treating diseases that respond to modulation of the serotonin 5-HT6 receptor. In formula I R is a moiety of the formula wherein * indicates the binding site to the quinolinyl radical and wherein A, B, X', Y, Q, R1, R2, R3, R4, R5, m, n, p, q, Ra, Rb, X and Ar are as defined in claim 1. |